

PENDING CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously presented) A method of reducing complement-mediated cytotoxicity in a mammal which comprises
identifying a mammal at risk of developing complement-mediated cytotoxicity; and
administering to said mammal, prior to tissue transplantation, a therapeutically effective amount of interleukin-11, wherein said amount of IL-11 reduces complement-mediated cytotoxicity in said mammal.

2. (Original) The method of claim 1, wherein the therapeutically effective amount of interleukin-11 comprises 1 to 100 $\mu\text{g/kg}$ body weight.

4 ~~3~~. (Previously presented) A method of ameliorating complement-mediated cytotoxicity in a mammal which comprises
identifying a mammal at risk of developing complement-mediated cytotoxicity; and
administering, at the time of tissue transplantation, a therapeutically effective amount of interleukin-11, wherein said amount of IL-11 ameliorates complement-mediated cytotoxicity in said mammal.

4. (Original) The method of claim ~~4~~, wherein the therapeutically effective amount of interleukin-11 comprises 1 to 100 $\mu\text{g/kg}$ body weight.

5. (Original) The method of claim ~~4~~, wherein the interleukin-11 is administered for three days beginning on the day of the tissue transplant.

6. (Cancelled)

7. (Original) The method of claim ~~7~~, wherein the therapeutically effective amount of interleukin-11 comprises 1 to 100 $\mu\text{g/kg}$ body weight.

8. (Previously presented) The method of claim ~~7~~, wherein the interleukin-11 is administered daily until improvement of the complement-mediated cytotoxicity disorder is observed.

9. (Previously presented) The method of claim ~~7~~, wherein the interleukin-11 is administered daily until remission of the complement-mediated disorder is observed.

3 ~~10~~. (Previously presented) The method of claim 1 wherein said mammal is a human.

11. (Previously presented) The method of claim ~~6~~ wherein said mammal is a human.

12-20. (Cancelled)

11 ~~21~~. (Previously presented) A method of treating complement-mediated cytotoxicity associated with organ or tissue transplantation in a mammal which comprises administering to said mammal a therapeutically effective amount of interleukin-11, wherein said amount of IL-11 reduces complement-mediated cytotoxicity in said mammal.

12 ~~22~~. (Previously presented) The method of claim ~~21~~, wherein the therapeutically effective amount of interleukin-11 comprises 1 to 100 $\mu\text{g/kg}$ body weight.